West African Emerging Infectious Disease Research Center (WA-EIDRC)

西非新发传染病研究中心 (WA-EIDRC)

• 批准号: 10653441
• 负责人: Kristian Graugaard Andersen
• 金额: $ 184.89万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-09 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10653441
• 关键词: 2019-nCoV; Acute; African; Award; COVID-19; COVID-19 pandemic; COVID-19 patient; Cessation of life; Detection; Diagnostic tests; Drug resistance; Emerging Communicable Diseases; Epidemiology; Evolution; Functional disorder; Funding; Goals; Immune; Immune response; Incidence; Incidence Study; Individual; Infectious Diseases Research; Lead; Oral; Parents; Pathogenesis; Paxlovid; Prevalence; Public Health; Rapid diagnostics; Reagent; Reporting; SARS-CoV-2 infection; Serology; Symptoms; System; Testing; Therapeutic; Viral Load result; Virus; Work; base; cohort; computerized tools; diagnostic assay; drug development; emerging pathogen; experience; improved; metagenomic sequencing; pathogen; programs; surveillance study; symptomatology; transmission process; treatment duration

PROJECT SUMMARY With the increasing use of oral antiviral treatments for acute SARS-CoV-2 infection, there have been multiple reports of symptom and viral load rebound after the prescribed treatment course. The most prescribed oral antiviral is Paxlovid, and while it has become a component of test-to-treat programs, there are no incidence or prevalence numbers on Paxlovid (symptomatologic and/or virologic) rebound after the five-day treatment course. Further, the connection between symptoms, viral load rebound, and immune correlates is unknown as well. This is of utmost urgence from a public health standpoint, given the possibility of the individual remaining infectious despite Paxlovid treatment and concerns about the potential development of drug resistance. Therefore, with additional funding we propose to study the incidence, prevalence, symptomatology, virus evolution, and immune correlates of COVID-19 cases who rebound after completion of Paxlovid treatment.

项目摘要 随着口服抗病毒治疗的急性SARS-COV-2感染的使用， 在规定后，已经有多个症状和病毒负荷反弹的报道 治疗课程。规定的口服抗病毒是paxlovid，虽然已成为 测试对治疗程序的组成部分，没有事件或患病率 五天治疗后，paxlovid（症状和/或病毒学）反弹。 此外，症状，病毒负荷反弹和免疫相关性之间的联系是 也未知。从公共卫生的角度来看，这是最迫切的 个人仍然存在感染任务的可能性Paxlovid治疗和关注 关于耐药性的潜在发展。因此，有了额外的资金 研究事件，患病率，症状，病毒进化和免疫的提议 在完成Paxlovid治疗后反弹的Covid-19病例相关。